This is extremely promising in mice models of MS and Spinal Cord Injuries that have shown reversals in CNS plaquing and scarring
The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
But the evidence points to multiple overlapping mechanisms that support tissue repair and protection
Patients may see them mentioned in the same forums, in the context of tendon injuries, muscle strains, joint pain, sports recovery, surgical recovery, or so-called Wolverine peptide stacks
Fractional lasers treat a percentage, or fraction, of the skin in the treatment area
A severe deficiency in vitamin B12 can result in demyelination
